- Home
- KOPN vs ZURA Comparison
KOPN vs ZURA Comparison
Compare KOPN & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOPN | ZURA |
|---|---|---|
| Founded | 1984 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.9M | 435.0M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | KOPN | ZURA |
|---|---|---|
| Price | $2.23 | $7.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $4.25 | ★ $11.78 |
| AVG Volume (30 Days) | ★ 2.0M | 482.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,044,337.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $45.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $0.99 |
| 52 Week High | $4.16 | $7.19 |
Technical Indicators
Market Signals| Indicator | KOPN | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 62.78 |
| Support Level | $1.67 | $5.62 |
| Resistance Level | $2.26 | N/A |
| Average True Range (ATR) | 0.14 | 0.50 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 28.07 | 90.07 |
Price Performance
Historical ComparisonAbout KOPN Kopin Corporation
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.